News
AI Won’t Solve Population Health On Its Own
MBC BioLabs recently hosted a conversation between Lee Sanders, MD, MPH, Professor of Pediatrics and Health Policy at Stanford University, and Leah Makley, PhD, COO at MBC BioLabs, to explore how the future of healthcare depends on keeping people, communities, and purpose at the center of innovation.
MBC BioLabs Announces New Partnership with ACROBiosystems Group
Through this collaboration, MBC BioLabs resident companies will gain enhanced access to ACROBiosystems' comprehensive portfolio of recombinant proteins, antibodies, kits, and scientific services - spanning targeted discovery and validation, candidate drug screening and optimization, CMC development, preclinical research, and clinical application.
MBC BioLabs Announces New Partnership with Deepcell
Through this partnership, MBC BioLabs resident companies will gain access to Deepcell’s AI-powered platform for single-cell analysis, as well as its REM-I equipment available on-site at 1030 Brittan.
MBC BioLabs Announces New Collaboration with Withum
Through this collaboration, MBC BioLabs resident companies will gain enhanced access to Withum's full suite of advisory, tax, and outsourced accounting services — from early-stage bookkeeping and R&D tax credits to CFO support, GAAP compliance, and audit services.
MBC BioLabs Announces New Partnership with Paul Hastings LLP
The new partnership with Paul Hastings LLP will strengthen our shared commitment to support high-growth biotech startups as they scale, innovate, and navigate an increasingly complex industry landscape.
Meiji Seika Pharma partners with MBC BioLabs to strengthen global innovation in drug discovery
Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic disorders, and immune-inflammatory diseases.
MBC BioLabs Announces New Partnership with Orchestra Bio
MBC BioLabs is proud to announce to announce a new partnership with Orchestra Bio. This collaboration will help support the mission of enabling awesome for MBC BioLabs’ community of high-growth biotech start-up companies.
MBC BioLabs Announces New Partnership with Araceli Biosciences
MBC BioLabs is proud to announce to announce a new partnership with Araceli Biosciences. This collaboration will help support the mission of enabling awesome for MBC BioLabs’ community of high-growth biotech start-up companies.
MBC BioLabs Announces New Partnership with Tecan
MBC BioLabs is proud to announce to announce a new partnership with Tecan. This collaboration will help support the mission of enabling awesome for MBC BioLabs’ community of high-growth biotech start-up companies.
MBC BioLabs Announces New Sponsorship Agreement with J.P. Morgan
MBC BioLabs is proud to announce it has entered into a sponsorship agreement with J.P. Morgan. This collaboration will help support the mission of enabling awesome for MBC BioLabs’ community of high-growth biotech start-up companies.
MBC BioLabs Announces New Partnership with Gilson
MBC BioLabs is proud to announce it has entered into a partnership with Gilson. This partnership will help support the mission of enabling awesome for MBC BioLabs’ community of high-growth biotech start-up companies.
MBC BioLabs Announces New Partnership with Opentrons
MBC BioLabs is proud to announce it has entered into a partnership with Opentrons. This partnership will help support the mission of enabling awesome for MBC BioLabs’ community of high-growth biotech start-up companies.
MBC BioLabs Announces New Partnership with Refeyn
MBC BioLabs is proud to announce it has entered into a partnership with Refeyn. This partnership will help support the mission of enabling awesome for MBC BioLabs’ community of high-growth biotech start-up companies.
MBC BioLabs Announces New Partnership with RWD Life Sciences
MBC BioLabs is proud to announce it has entered into a partnership with RWD Life Sciences. This partnership will help support the mission of enabling awesome for MBC BioLabs’ community of high-growth biotech start-up companies.
MBC BioLabs Announces New Partnership with Twist Bioscience
MBC BioLabs is proud to announce it has entered into a partnership with Twist Bioscience. This partnership will help support the mission of enabling awesome for MBC BioLabs’ community of high-growth biotech start-up companies.
MBC BioLabs Announces New Partnership with Quantum-SI
MBC BioLabs is proud to announce it has entered into a partnership with Quantum-SI. This partnership will help support the mission of enabling awesome for MBC BioLabs’ community of high-growth biotech start-up companies.
MBC BioLabs Announces New Partnership with Element Bioscience
MBC BioLabs is proud to announce it has entered into a partnership with Element Biosciences. This partnership will help support the mission of enabling awesome for MBC BioLabs’ community of high-growth biotech start-up companies.
BioInnovation Labs (BioLabs), LabCentral and MBC BioLabs Announce Strategic Partnership with AbbVie to Boost Innovation in key biotech clusters in the US and Europe.
BioLabs, LabCentral and MBC BioLabs are excited to announce a five-year strategic partnership with AbbVie, a global biopharmaceutical company. AbbVie has long been a champion of the three organizations’ shared vision for advancing biotech entrepreneurship and continues to play a critical role in the networks they have cultivated over the past decade.
Alumnus Spotlight on Meet Vora
GraphWear has raised $28 million in funding to date, enabling critical advancements in its technology and expanding its reach through clinical trials and strategic collaborations. As an MBC BioLabs alumnus, Meet’s story exemplifies the entrepreneurial spirit and dedication fostered by the MBC BioLabs community, reflecting how innovation can thrive from modest beginnings.
BridgeBio’s Attruby™ (acoramidis) approved by FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients
The U.S. Food and Drug Administration (FDA) approved Attruby™ (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. The FDA approval is based on positive results seen in the ATTRibute-CM Phase 3 study, where Attruby significantly reduced death and cardiovascular-related hospitalization, and improved quality of life.
OneSkin closes $20M series A investment round, fueling the future of skin longevity with advanced research
OneSkin is a best-in-class biotech skin health brand on a mission to revolutionize how we age. Created by four pioneering female scientists - OneSkin believes in research first, products second. That's why its founders spent five years analyzing over 900 peptides before discovering OS-01, the first ingredient scientifically proven to reverse skin's biological age.
Myka Labs partners with Mayo Clinic to develop next-gen AI for surgery
The Myka Labs-Mayo Clinic collaboration has a near-term focus on developing tools for gastroenterologists and surgeons performing procedures to diagnose and treat disease in the pancreas and other abdominal organs, with a longer-term view toward developing wide-ranging artificial intelligence-based innovations that positively impact patient care across a broad spectrum of medical conditions.
Dren Bio Announces Strategic Collaboration with Novartis
We are thrilled to share the news of a strategic collaboration between Dren Bio, one of our distinguished alumni, and Novartis to develop bispecific antibody therapies targeting cancer. This partnership, which builds on Dren Bio’s targeted myeloid engager and phagocytosis platform, includes an upfront payment of $150 million from Novartis, with $25 million as an equity investment.